

SOLIGENIX, INC.  
Form SC 13G  
September 19, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**SCHEDULE 13G**  
**Under the Securities Exchange Act of 1934**  
**(Amendment No.    )\***

**Soligenix, Inc.**

**(Name of Issuer)**

**Common Stock, par value \$0.001 per share**

**(Title of Class of Securities)**

**834223208**

**(CUSIP Number)**

**9 September 2016**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13G**

**CUSIP No.** 834223208

**1** NAME OF REPORTING PERSON

SciClone Pharmaceuticals, Inc.\*

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
94-3116852

(a) " (b) "

**3** SEC USE ONLY

**4** CITIZENSHIP OR PLACE OF ORGANIZATION

State of Delaware

**5** SOLE VOTING POWER

NUMBER OF

SHARES **6** 3,529,412 shares\*  
SHARED VOTING POWER

BENEFICIALLY

OWNED BY **7** 0 shares  
EACH SOLE DISPOSITIVE POWER

REPORTING

PERSON **8** 3,529,412 shares\*  
SHARED DISPOSITIVE POWER

WITH

0 shares

**9** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,529,412 shares\*

**10** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

9.43%\*

**12** TYPE OF REPORTING PERSON

CO

\* The shares are held by SciClone Pharmaceuticals International China Holding Limited, an indirect wholly-owned subsidiary of SciClone Pharmaceuticals, Inc.

**SCHEDULE 13G**

**CUSIP No.** 834223208

**Item 1.** (a). Name of Issuer:

Soligenix, Inc.

(b). Address of issuer's principal executive offices:

29 Emmons Drive, Suite C-10

Princeton, NJ 08540

**Item 2.** (a). Name of person filing:

SciClone Pharmaceuticals, Inc.

(b). Address or principal business office or, if none, residence:

950 Tower Lane, Suite 900,

Foster City, CA 94404

(c). Citizenship:

State of Delaware

(d). Title of class of securities:

Common Stock

(e). CUSIP No.:

834223208

---

**SCHEDULE 13G**

**CUSIP No.** 834223208

- Item 3.** If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
- (a) " Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  - (b) " Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  - (c) " Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  - (d) " Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  - (e) " An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  - (f) " An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
  - (g) " A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  - (h) " A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
  - (i) " A church plan that is excluded from the definition of an investment company under section 3<sup>©</sup>(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  - (j) " A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  - (k) " Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

**SCHEDULE 13G**

**CUSIP No.** 834223208

**Item 4. Ownership.**

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:  
3,529,412 shares\*

(b) Percent of class:  
9.43%\*

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote  
3,529,412 shares\*

(ii) Shared power to vote or to direct the vote  
0

(iii) Sole power to dispose or to direct the disposition of  
3,529,412 shares\*

(iv) Shared power to dispose or to direct the disposition of  
0

Instruction: For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following " ".

**Item 6. Ownership of More Than Five Percent on Behalf of Another Person.**

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A



**SCHEDULE 13G**

**CUSIP No.** 834223208

**Item 8. Identification and Classification of Members of the Group.**

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

**Item 9. Notice of Dissolution of Group.**

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Dated: September 19, 2016

**SciClone Pharmaceuticals, Inc.**

By: /s/ Wilson W. Cheung  
Wilson W. Cheung

Chief Financial Officer and

Senior Vice President, Finance

